Resection or Ablation of Small Kidney Tumors
NCT06278506
Summary
Ablative treatments are believed to have a lower rate of complications, shorter hospital stays, and fewer interventions with benign PAD compared to partial nephrectomies in small kidney cancer lesions. The purpose of the study is to compare complications, the frequency of residual tumors, impact on kidney function, differences in quality of life, and health economic factors in a randomised study. We will also compare the oncological outcomes, including survival and recurrence of kidney cancer.
Eligibility
Inclusion Criteria: * Age 18 - 99 years * Patient suitable based on clinical status for both ablative treatment and surgery * Primary kidney tumor * Tumor size ≤ 3 cm * Clinical stage of the tumor T1a (no macroscopic vascular or extrarenal invasion) * Tumor location suitable for both ablative treatment and resection * Absence of radiological signs of metastasis * Biopsy with malignant pathological analysis (PAD) * ISUP grade I-III" Exclusion Criteria: * Radiological signs of metastasis * Synchronous kidney tumors * ISUP grade IV or sarcomatoid growth in the biopsy * Other metastasized cancer in the last 5 years * Patient unable to make an informed decision to participate in the study
Conditions2
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06278506